var data={"title":"Iothalamate meglumine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iothalamate meglumine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6392?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iothalamate-meglumine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iothalamate meglumine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535894\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Not for intrathecal use. Solution for instillation is also not for intravascular administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183983\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Conray;</li>\n      <li>Conray 30;</li>\n      <li>Conray 43;</li>\n      <li>Cysto-Conray II</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15793707\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Conray 30;</li>\n      <li>Conray 43;</li>\n      <li>Conray 60;</li>\n      <li>Cysto-Conray II</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183986\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Ionic, High Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26526735\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note</b>: Concentration, volume, and rate may depend on the equipment, condition of injected vessel, size/condition of patient, and imaging technique used. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Intravascular imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Arterial digital subtraction angiography: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 30, Conray 43: Usual dose: Carotid or vertebral arteries: 3 to 10 mL; aortic arch: 15 to 30 mL; subclavian and brachial arteries: 5 to 15 mL; major branches of the aorta: 5 to 30 mL; abdominal aorta: 10 to 30 mL; maximum: 250 mL (Conray 30) or 200 mL (Conray 43)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray: Usual dose: Carotid or vertebral arteries: 3 to 8 mL; aortic arch: 15 to 25 mL; subclavian and brachial arteries: 5 to 15 mL; major branches of the aorta: 5 to 20 mL; lumbar aorta (bifurcation): 10 to 25 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Arthrography:</i> Conray: Usual dose: 5 to 15 mL (knee, hip), 5 to 10 mL (shoulder, ankle), 1 to 4 mL (other)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Carotid and vertebral angiography:</i> Conray: Usual dose: 6 to 10 mL; repeat as indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Contrast enhancement of body CT:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Usual dose: 200 to 250 mL by bolus injection, rapid infusion or both; when using the combination bolus and infusion technique, 50 to 100 mL bolus injection followed by a rapid infusion of 100 to 150 mL may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vascular opacification: 25 to 50 mL by bolus injection; repeat as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prolonged arterial or venous phase enhancement and enhancement of specific lesions: 150 mL rapid infusion; 100 to 150 mL infusion may be employed to define the area of interest followed by bolus injections of 20 to 50 mL to clarify selected scans.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Contrast enhancement of brain CT:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 30: Usual dose: 200 to 300 mL; for patients weighing &lt;45 kg, 4 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Usual dose: 3 mL/kg (maximum dose: 200 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray: Usual dose: 2 mL/kg (maximum: 150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Cranial computerized angiotomography: </i> Conray: Usual dose: May be given by bolus injection (0.5 to 1 mL/kg at an injection rate of 2 mL/second; repeat dose as needed [maximum total dose per procedure: 200 mL]) <b>OR</b> by bolus injection followed by IV infusion (50 mL bolus injection followed by a rapid infusion of 150 mL <b>OR</b> 100 mL bolus injection followed by a rapid infusion of 100 mL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Direct cholangiography:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Operative/postoperative: Conray: Usual dose: 10 to 25 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Percutaneous transhepatic cholangiography: Conray: Usual dose: 20 to 40 mL; may repeat for exposures in different planes. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Endoscopic retrograde cholangiopancreatography:</i>  Conray: Usual dose: 10 to 100 mL (common bile duct); 2 to 10 mL (pancreatic duct); administer under fluoroscopic control </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Excretory urography: </i> Conray: Usual dose: 30 to 60 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Intravenous digital subtraction angiography: </i>  Conray: Usual dose: 20 to 40 mL; repeat as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Peripheral arteriography: </i> Conray: Usual dose: 20 to 40 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Retrograde brachial cerebral angiography: </i> Conray: Usual dose: 35 to 50 mL into the right brachial artery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Urography: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 30: Usual dose: 200 to 300 mL (4 mL/kg) (maximum dose: 300 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Usual dose: 3 mL/kg (maximum dose: 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Venography:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Usual dose: 30 to 125 mL per lower extremity </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray: Usual dose: 20 to 40 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Urographic imaging: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Retrograde cystography and cystourethrography:</i> Conray 43 and Cysto-Conray II: Usual dose: 200 to 400 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Retrograde pyelography: </i> Conray 43: Usual dose: 25 mL for bilateral and 15 mL for unilateral pyelograms; 5 to 6 mL usually administered for each exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26526708\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Concentration, volume, and rate may depend on the equipment, condition of injected vessel, size/condition of patient, and imaging technique used. Refer to prescribing information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intravascular imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Arthrography, cerebral angiography, cranial computerized angiotomography, peripheral arteriography/venography:</i> Conray: Children and Adolescents: Refer to adult dosing; reduce dosage in approximate proportion to age and body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lower extremity venography:</i> Conray 43: Children and Adolescents: Refer to adult dosing; reduce dosage in approximate proportion to age and body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Contrast enhancement of brain CT:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 30:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &lt;12 years and &lt;45 kg: Usual dose: 4 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;12 years and &ge;45 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray: Children and Adolescents: Usual dose: 2 mL/kg (maximum: 150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Contrast enhancement of body CT:</i> Conray 43: Children and Adolescents: Refer to adult dosing; reduce dosage in approximate proportion to age and body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Excretory urography:</i> Conray:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;14 years: Usual dose: 0.5 mL/kg (up to 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;14 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Urography:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 30: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conray 43: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Urographic imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Retrograde cystography and cystourethrography:</i> Conray 43 and Cysto-Conray II: Children and Adolescents: Usual dose: 30 to 300 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Retrograde pyelography:</i> Conray 43: Children and Adolescents: Refer to adult dosing; reduce dosage in approximate proportion to body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962272\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962273\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the  manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183975\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Conray: 60% (30 mL, 50 mL, 100 mL, 150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Conray 30: 30% (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Conray 43: 43% (50 mL, 250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Urethral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cysto-Conray II: 17.2% (250 mL, 500 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183971\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26526746\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection: Not for intrathecal use. Administration recommendations vary by product and indication; refer to prescribing information for detailed administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast media should be at or close to body temperature when injected. Patient should omit the meal that precedes the examination. Appropriate premedication (eg, barbiturate, tranquilizer or an analgesic) may be administered prior to the examination. Patients with a strong allergic history may receive an antihistamine within 30 minutes of administration of the contrast agent and corticosteroids prior to and for 24 hours after the contrast agent. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do not flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase</i>: Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara, 1983; Zenk, 1981) or injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett, 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Solution for instillation: Not for intrathecal or intravascular use. Administer into the urinary bladder by gravity flow using an appropriate venoclysis set or by syringe. Avoid excessive pressure. Unless contraindicated, a laxative should be administered the night before the examination. Consider premedication with an antihistamine and/or a corticosteroid prior to administration of the contrast agent in patients with a strong allergic history.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183976\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conray: Excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of CT brain images, cranial computerized angiotomography, IV digital subtraction angiography and arterial digital subtraction angiography; enhancement of CT scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conray 30: IV infusion urography, contrast enhancement of computed tomographic (CT) brain images and arterial digital subtraction angiography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conray 43: Lower extremity venography, IV infusion urography, contrast enhancement of CT brain images and arterial digital subtraction angiography; enhancement of CT scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space; retrograde cystography, cystourethrography and retrograde pyelography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysto-Conray II: Retrograde cystography and cystourethrography. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174551\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872205\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Reactions may be class effects rather than specific to this product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac fibrillation, cerebrovascular accident, chest tightness, coronary insufficiency, decreased blood pressure, duodenal wall intravasation, facial edema, facial flushing, flushing, hypotensive shock, peripheral edema, syncope, tachycardia, thrombophlebitis, thrombosis, vasoconstriction, vasodilatation, venospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Amnesia, aphasia, chills, choking sensation, coma, convulsions, dizziness, flushing sensation, headache, localized burning paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, diaphoresis, DRESS syndrome, ecchymoses, erythema, gangrene, maculopapular rash, pruritus, skin discoloration, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Altered thyroid hormone levels (transient suppression; premature infants and infants with underlying medical conditions may be more vulnerable; FDA Safety Alert 2015), hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, pancholangitis, pancreatitis, severe abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal erythropoiesis, disseminated intravascular coagulation, erythrocyte agglutination, hematoma, hemorrhage, interference in clot formation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Septicemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Extravasation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, brachial plexus injury, laryngospasm, muscle spasm, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival abnormalities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal disease, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, bronchospasm, cough, cyanosis, dyspnea, exacerbation of asthma, nasal congestion, pulmonary edema, sneezing, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, tissue necrosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183978\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to iothalamate meglumine or any component of the formulation; intrathecal administration; intravascular administration (solution for instillation); myelography (solution for injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Refer to product labeling for product and procedure specific contraindications</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26525574\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered in patient at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. Begin corticosteroids early prior to contrast media and continue for 24 hours after administration. Administer antihistamines within 30 minutes before contrast agent. Monitor closely for 30 to 60 minutes after administration of the contrast media and discontinue immediately if a serious reaction occurs. For minor reactions the infusion may be slowed or interrupted until the reaction subsides. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iothalamate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Ioxaglate meglumine is hypertonic. Burning pain, hematomas, bruising, thrombophlebitis, and tissue necrosis have been reported with extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Serious neurologic sequelae, including paralysis (permanent) may occur following cerebral arteriography, selective spinal arteriography, and arteriography of vessels supplying the spinal cord. Do not inject contrast media after administration of vasopressors; may potentiate neurologic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, in diabetic patients with diabetic nephropathy, susceptible nondiabetic patients (eg, elderly patients with preexisting renal disease), and patients with occult renal disease (particularly patients with diabetes and/or hypertension); avoid fluid restriction and maintain normal hydration in these patients. Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing MI and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebral lesions: Seizures have occurred in patients with cerebral lesions (primary or metastatic) following administration of contrast agent for CT brain images.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endotoxemia: Contrast media studies should be undertaken with caution in patients with endotoxemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients combined renal and hepatic disease; excretion may be impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthermia: Contrast media studies should be undertaken with caution in patients with elevated body temperatures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants). Some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma; use of intravascular contrast agents may lead to irreversible progressive anuria, renal impairment, and death. Dehydration may be a causative factor; partial dehydration in preparation for procedures may precipitate myeloma protein in renal tubules and is not recommended in myeloma patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure closely throughout procedure. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with advanced renal disease. Excretion may be impaired; use only if clearly needed. Patients with combined renal and hepatic disease, severe hypertension or heart failure, and recent renal transplant are at increased risk for impaired excretion. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in homozygous sickle cell patients; administration may result in disease exacerbation. Fluid restriction is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subarachnoid hemorrhage: In patients with subarachnoid hemorrhage, contrast administration may be associated with deterioration in clinical status (including seizure and fatality); administer with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract infection: Use solution for instillation with caution in patients with acute UTI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Preparatory dehydration may contribute to acute renal failure in elderly patients; avoid fluid restriction and maintain normal hydration in elderly patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Preparatory dehydration may contribute to acute renal failure in infants and young children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: NOT for intrathecal use. Solution for instillation is also NOT for intravascular administration</b>. Serious adverse reactions (including death, seizure, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema) have been reported due to inadvertent intrathecal administration of iodinated contrast agents not indicated for intrathecal use. In contrast-enhanced computerized tomography (CECT), contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299533\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221105\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8960&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183973\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (product dependent) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183980\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. In general, iodinated contrast media agents may cross the placenta; use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183981\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Iothalamate salts are present in breast milk. Because of the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends bottle feedings for 24 hours after administration. Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant&rsquo;s GI tract, other sources note breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26526776\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, blood pressure, hydration; monitor for extravasation during IV administration; monitor for hypersensitivity reactions for &ge;30 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct cholangiography: Monitor patient for &ge;24 hours to ensure prompt detection of bile leakage and hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endoscopic retrograde cholangiopancreatography: Monitor patient for 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral arteriography/venography: Monitor blood pressure for 10 minutes following injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26525578\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radiopaque contrast agent; opacifies vessels in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures of the body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26526601\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Rapid (following intravascular administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily and as unchanged drug); feces (minor)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323207\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Conray 30 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30% (150 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Conray 43 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">43% (50 mL): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Conray Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60% (50 mL): $17.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cysto-Conray II Urethral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.2% (250 mL): $27.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038660\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Conray (AU, EG, QA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iothalamate-meglumine-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conray (iothalamate) [prescribing information]. St. Louis, MO: Mallinckrodt; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conray 30 (iothalamate) [prescribing information]. St. Louis, MO: Mallinckrodt; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conray 43 (iothalamate) [prescribing information]. St. Louis, MO: Mallinckrodt; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cysto-Contray II (iothalamate) [prescribing information]. St. Louis, MO: Mallinckrodt; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iothalamate-meglumine-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iothalamate-meglumine-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of Intravenous Extravasations. Infusion. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8960 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26535894\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183983\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F15793707\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183986\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26526735\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26526708\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962272\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962273\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183975\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183971\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26526746\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183976\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174551\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F25872205\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183978\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26525574\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299533\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221105\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183973\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183980\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183981\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26526776\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26525578\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26526601\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323207\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038660\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8960|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iothalamate-meglumine-patient-drug-information\" class=\"drug drug_patient\">Iothalamate meglumine: Patient drug information</a></li></ul></div></div>","javascript":null}